These results support tightening alcohol use guidance in the United States, for both males and females, to no more than 1 drink per day.
Searching for Solutions
NIH has cleared a first-in-human safety study of mitragynine, the primary alkaloid in kratom, to assess whether this opioid-receptor compound could be developed as a treatment for opioid use disorder. The move reflects both the promise seen in preclinical research and the central concern that kratom is itself psychoactive and potentially addictive, making safety and tolerability the immediate question.
The U.S. Drug Enforcement Administration opened a long-awaited administrative hearing June 29 on a proposal to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, with proceedings expected to run into mid-July. A shift to Schedule III would formally recognize accepted medical use and ease research restrictions. AAPP supports the rescheduling of cannabis to enable the necessary research.
Learn how wearable technology can enhance well-being, including prevention, treatment, and recovery for mental health and substance use.
The FDA has approved for eligible adults with early Alzheimer Disease to start lecanemab using weekly subcutaneous autoinjectors at home. The starting does is 500 mg weekly followed by 360 mg once weekly as maintenance.
A combination of THC and CBD eased symptoms in an especially frail population: patients with advanced dementia near the end of their lives.
Half as many young adults are misusing Adderall, Ritalin and other ADHD medications these days to help them remain alert at study or work, a new evidence review says. Misuse of ADHD stimulant meds among adults under 30 fell from 7.5% in 2016 to 3.7% in 2023, researchers report in the Journal of Clinical Psychopharmacology.
A new Primary Care Investment Guide from the Harvard Medical School Center for Primary Care outlines evidence-based strategies for strengthening advanced primary care while improving outcomes and lowering costs. Developed with support from the California Health Care Foundation and the Commonwealth Fund, the guide identifies integrated clinical pharmacy services as a key investment alongside behavioral health, care management and population health.
AAPP has released requests related to implementation of federal policies that reduce access to nicotine-containing products among teens and adolescents including flavored vaping products that increase youth appeal. Additionally, with increased incidence of gambling disorder and problem gambling, AAPP has issued support for increased research into and access to treatment given that there are currently no FDA-approved medications for treatment of gambling disorder.
AAPP's Psychotropic LAI Training Program is back and full of updates! This grant-funded educational activity is offered complimentary and includes access to 6 webinars and LAI resources like a pocket-guide, administration videos, and more. Register today and help us share this program with others that would find it valuable.
No summary available
This toolkit on urine drug screens provides reasons for unexpected results, expected metabolites for opioids with confirmation testing, evaluation of urine, and potential positive results with immunoassays and detection time in the urine.
No summary available
No summary available
Despite strong training, new psychiatric pharmacists will encounter challenging trainees throughout their career. Here are 5 guidelines to prevent rotation problems.
The FDA reversed years of strict enforcement against flavored vapes by authorizing the first legal fruit-flavored e-cigarettes for adults over 21. AAPP supports policies that reduce access to products such as flavored vapes that are attractive to youth.
No summary available
10
hours
hours
Expired
No summary available
10
hours
hours
Expired
No summary available
20
hours
hours
Expired
Gambling disorder and problem gambling research and treatment are needed and supported by AAPP given the limited research on screening and treatment of gambling disorder.
Well over 1,100 students join AAPP each year to learn more about the profession and how to advance their careers. From networking and mentoring to education and toolkits, AAPP works to promote the development of the next generation of psychiatric pharmacists.
Join Dr. Clayton English during the #2026AAPPSummit on Oct. 1 for a session on Treatment of ADHD in Older Adults. Sessions are eligible for ACPE and BCPP recertification credit!
Join Dr. Teresa DeLellis during the #2026AAPPSummit on Oct. 2 for a session on Bridging Science and Support: Integrating New Alzheimer’s Disease Treatments into Clinical Practice. Sessions are eligible for ACPE and BCPP recertification credit!
Join Dr. Carol Ott during the #2026AAPPSummit on Oct. 1 for a session on Bridging Minds and Hormones: Psychiatric Considerations in Hormone Therapy. Sessions are eligible for ACPE and BCPP recertification credit!
Join Dr. Kara Wong during the #2026AAPPSummit on Oct. 2 for a session on Partial Agonist, Full Potential: Evidence-Based Use of Buprenorphine in Chronic Pain Management. Sessions are eligible for ACPE and BCPP recertification credit!